Kezar Life Sciences (Kezar Life Sciences) Market Cap : $56.05 Mil (As of May. 20, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Kezar Life Sciences Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Kezar Life Sciences's share price for the quarter that ended in Mar. 2024 was $0.9016. Kezar Life Sciences's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 72.80 Mil. Therefore, Kezar Life Sciences's market cap for the quarter that ended in Mar. 2024 was $65.64 Mil.

Kezar Life Sciences's quarterly market cap declined from Sep. 2023 ($86.50 Mil) to Dec. 2023 ($68.95 Mil) and declined from Dec. 2023 ($68.95 Mil) to Mar. 2024 ($65.64 Mil).

Kezar Life Sciences's annual market cap declined from Dec. 2021 ($940.66 Mil) to Dec. 2022 ($482.19 Mil) and declined from Dec. 2022 ($482.19 Mil) to Dec. 2023 ($68.95 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Kezar Life Sciences's Enterprise Value for Today is $-105.77 Mil.

Kezar Life Sciences Market Cap Historical Data

The historical data trend for Kezar Life Sciences's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kezar Life Sciences Market Cap Chart

Kezar Life Sciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Market Cap

Get a 7-Day Free Trial

77.02

242.00

940.66

482.19

68.95

Kezar Life Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Market Cap	Get a 7-Day Free Trial															221.65	177.71	86.50	68.95	65.64

Competitive Comparison of Kezar Life Sciences's Market Cap

For the Biotechnology subindustry, Kezar Life Sciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kezar Life Sciences's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kezar Life Sciences's Market Cap distribution charts can be found below:

* The bar in red indicates where Kezar Life Sciences's Market Cap falls into.

Kezar Life Sciences Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Kezar Life Sciences's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )	=	Share Price (A: Dec. 2023 )	*	Shares Outstanding (EOP) (A: Dec. 2023 )
	=	$0.9474	*	72.7791
	=	$68.95

Kezar Life Sciences's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )	=	Share Price (Q: Mar. 2024 )	*	Shares Outstanding (EOP) (Q: Mar. 2024 )
	=	$0.9016	*	72.8014
	=	$65.64

Kezar Life Sciences (NAS:KZR) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Kezar Life Sciences Market Cap Related Terms

Thank you for viewing the detailed overview of Kezar Life Sciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Kezar Life Sciences (Kezar Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kezar Life Sciences Inc (NAS:KZR) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

2KZ:Germany 2KZ:Germany

Address

4000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.kezarlifesciences.com

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as KZR-616, and the protein secretion program.

Executives

Morningside Venture Investments Ltd	10 percent owner	MCCARTHY LEGAL SERVICES, 1188 CENTRE STREET, NEWTON CENTRE MA 02459
Nicholas Michael Mordwinkin	officer: Chief Business Officer	C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Franklin M Berger	director	1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Wallace Courtney	director	C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Micki Klearman	director	C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Equal Talent Investments Ltd	10 percent owner	THC MANAGEMENT SERVICES S.A.M. 2ND FLOOR, LE PRINCE DE GALLES 3-5 AVE DE CITRONNIE, MONTE CARLO O9 98000
Noreen Henig	officer: Chief Medical Officer	C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
John Franklin Fowler	director, officer: CEO	C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Christopher J. Kirk	director, officer: President and CSO	C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Marc Belsky	officer: Chief Financial Officer	C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Vassiliki Economides	officer: SVP, Strategy & External Aff.	C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Elizabeth Garner	director	101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Gp, Llc	10 percent owner	100 HIGH STREET, SUITE 1105, BOSTON DC 02110
Bay City Capital Llc	10 percent owner	750 BATTERY STREET STE 400, SAN FRANCISCO CA 94111